Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

https://ift.tt/os9kIx3

Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

from Sanofi - Aventis Groupe https://ift.tt/XGJmAoH
via IFTTT

" May good health envelop you, spurring a quick recovery. .. "

from health care https://ift.tt/ZzGk5B0
via IFTTT https://ift.tt/UkPpiun